Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1075 in GT1 and GT3 HCV Infected Patients
NCT02461563Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of MK-1075 in hepatitis C (HCV) (6 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experienced an Adverse Event, Number of Participants Who Discontinued Treatment Due to an Adverse Event and 1 more. Started Jun 2015; status: completed.
02
Drugs
MK-1075
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02461563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02461563.